Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins
Díez, José María (Grifols. Bioscience Research & Development)
Romero, Carolina (Grifols. Bioscience Research & Development)
Vergara-Alert, Júlia (Institut de Recerca i Tecnologia Agroalimentàries. Centre de Recerca en Sanitat Animal)
Belló-Perez, Melissa (Laboratorio Coronavirus. Departamento de Biología Molecular y Celular)
Rodon, Jordi (Institut de Recerca i Tecnologia Agroalimentàries. Centre de Recerca en Sanitat Animal)
Honrubia, José Manuel (Laboratorio Coronavirus. Departamento de Biología Molecular y Celular)
Segalés Coma, Joaquim (Universitat Autònoma de Barcelona. Departament de Sanitat i d'Anatomia Animals)
Sola, Isabel (Laboratorio Coronavirus. Departamento de Biología Molecular y Celular)
Enjuanes, Luis (Laboratorio Coronavirus. Departamento de Biología Molecular y Celular)
Gajardo, Rodrigo (Grifols. Bioscience Research & Development)

Date:	2020
Abstract:	Background: Cross-reactivity against human coronaviruses with Flebogamma ® DIF and Gamunex ® -C, two available intravenous immunoglobulins (IVIG), has been reported. In this study, these IVIG were tested for neutralization activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), SARS-CoV and Middle East respiratory syndrome CoV (MERS-CoV). Materials & methods: Neutralization capacity of lots of IVIG manufactured prior to COVID-19 pandemic was assessed against these viruses in cell culture. Infectivity neutralization was quantified by percent reduction in plaque-forming units and/or cytopathic/cytotoxic methods. Results: All IVIG preparations showed neutralization of SARS-CoV-2 isolates. All IVIG lots produced neutralization of SARS-CoV. No IVIG preparation showed significant neutralizing activity against MERS-CoV. Conclusion: The tested IVIG contain antibodies with significant in vitro cross-neutralization capacity against SARS-CoV-2 and SARS-CoV, but not MERS-CoV. These preparations are currently under evaluation as potential therapies for COVID-19.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	COVID-19 ; Cross-neutralization ; Intravenous immunoglobulin ; MERS-CoV ; SARS-CoV ; SARS-CoV-2
Published in:	Immunotherapy, september 2020, ISSN 1750-7448

DOI: 10.2217/imt-2020-0220
PMID: 32900263

10 p, 917.8 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Centre de Recerca en Sanitat Animal (CReSA-IRTA)
Articles > Research articles
Articles > Published articles